Literature DB >> 21628671

Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine.

Lilin Lai1, Suefen Kwa, Pamela A Kozlowski, David C Montefiori, Guido Ferrari, Welkin E Johnson, Vanessa Hirsch, Francois Villinger, Lakshmi Chennareddi, Patricia L Earl, Bernard Moss, Rama Rao Amara, Harriet L Robinson.   

Abstract

A simian immunodeficiency virus (SIV) vaccine coexpressing granulocyte-macrophage colony stimulating factor (GM-CSF) prevented infection in 71% of macaques that received 12 rectal challenges. The SIVsmE660 challenge had the tropism of incident human immunodeficiency virus (HIV) infections and a similar genetic distance from the SIV239 vaccine as intraclade HIV isolates. The heterologous prime-boost vaccine regimen used recombinant DNA for priming and recombinant modified vaccinia Ankara for boosting. Co-expression of GM-CSF in the DNA prime enhanced the avidity of elicited immunoglobulin G for SIV envelope glycoproteins, the titers of neutralizing antibody for easy-to-neutralize SIV isolates, and antibody-dependent cellular cytotoxicity. Impressively, the co-expressed GM-CSF increased vaccine-induced prevention of infection from 25% in the non-GM-CSF co-expressing vaccine group to 71% in the GM-CSF co-expressing vaccine group. The prevention of infection showed a strong correlation with the avidity of the elicited Env-specific antibody for the Env of the SIVsmE660 challenge virus (r = 0.9; P < .0001).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21628671      PMCID: PMC3143670          DOI: 10.1093/infdis/jir199

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

1.  Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination.

Authors:  Vijayakumar Velu; Sunil Kannanganat; Chris Ibegbu; Lakshmi Chennareddi; Francois Villinger; Gordon J Freeman; Rafi Ahmed; Rama Rao Amara
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

2.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

Authors:  Paola Filipazzi; Roberta Valenti; Veronica Huber; Lorenzo Pilla; Paola Canese; Manuela Iero; Chiara Castelli; Luigi Mariani; Giorgio Parmiani; Licia Rivoltini
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

3.  Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Authors:  James M Binley; Elizabeth A Lybarger; Emma T Crooks; Michael S Seaman; Elin Gray; Katie L Davis; Julie M Decker; Diane Wycuff; Linda Harris; Natalie Hawkins; Blake Wood; Cory Nathe; Douglas Richman; Georgia D Tomaras; Frederic Bibollet-Ruche; James E Robinson; Lynn Morris; George M Shaw; David C Montefiori; John R Mascola
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

4.  Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Authors:  D Noah Sather; Jakob Armann; Lance K Ching; Angeliki Mavrantoni; George Sellhorn; Zachary Caldwell; Xuesong Yu; Blake Wood; Steve Self; Spyros Kalams; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

5.  Granzyme B activity in target cells detects attack by cytotoxic lymphocytes.

Authors:  Beverly Z Packard; William G Telford; Akira Komoriya; Pierre A Henkart
Journal:  J Immunol       Date:  2007-09-15       Impact factor: 5.422

6.  Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Rachel M Klein; Maura M Manion; Sijy O'Dell; Adhuna Phogat; Bimal Chakrabarti; Claire W Hallahan; Stephen A Migueles; Jens Wrammert; Rafi Ahmed; Martha Nason; Richard T Wyatt; John R Mascola; Mark Connors
Journal:  J Virol       Date:  2008-10-15       Impact factor: 5.103

7.  Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells.

Authors:  Sunil Kannanganat; Chris Ibegbu; Lakshmi Chennareddi; Harriet L Robinson; Rama Rao Amara
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

8.  GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine.

Authors:  Lilin Lai; Dalma Vödrös; Pamela A Kozlowski; David C Montefiori; Robert L Wilson; Vicki L Akerstrom; Lakshmi Chennareddi; Tianwei Yu; Sunil Kannanganat; Lazarus Ofielu; Francois Villinger; Linda S Wyatt; Bernard Moss; Rama Rao Amara; Harriet L Robinson
Journal:  Virology       Date:  2007-08-14       Impact factor: 3.616

9.  Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.

Authors:  Linda S Wyatt; Igor M Belyakov; Patricia L Earl; Jay A Berzofsky; Bernard Moss
Journal:  Virology       Date:  2007-11-28       Impact factor: 3.616

10.  Macaques vaccinated with live-attenuated SIV control replication of heterologous virus.

Authors:  Matthew R Reynolds; Andrea M Weiler; Kim L Weisgrau; Shari M Piaskowski; Jessica R Furlott; Jason T Weinfurter; Masahiko Kaizu; Taeko Soma; Enrique J León; Caitlin MacNair; Dan P Leaman; Michael B Zwick; Emma Gostick; Solomon K Musani; David A Price; Thomas C Friedrich; Eva G Rakasz; Nancy A Wilson; Adrian B McDermott; Rosanne Boyle; David B Allison; Dennis R Burton; Wayne C Koff; David I Watkins
Journal:  J Exp Med       Date:  2008-10-06       Impact factor: 14.307

View more
  70 in total

1.  Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia.

Authors:  Shari N Gordon; Melvin N Doster; Rhonda C Kines; Brandon F Keele; Egidio Brocca-Cofano; Yongjun Guan; Poonam Pegu; Namal P M Liyanage; Monica Vaccari; Nicolas Cuburu; Christopher B Buck; Guido Ferrari; David Montefiori; Michael Piatak; Jeffrey D Lifson; Anastasia M Xenophontos; David Venzon; Marjorie Robert-Guroff; Barney S Graham; Douglas R Lowy; John T Schiller; Genoveffa Franchini
Journal:  J Immunol       Date:  2014-11-14       Impact factor: 5.422

2.  Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys.

Authors:  Kathryn E Stephenson; Hualin Li; Bruce D Walker; Nelson L Michael; Dan H Barouch
Journal:  J Virol       Date:  2012-07-03       Impact factor: 5.103

3.  Decreased T Follicular Regulatory Cell/T Follicular Helper Cell (TFH) in Simian Immunodeficiency Virus-Infected Rhesus Macaques May Contribute to Accumulation of TFH in Chronic Infection.

Authors:  Ankita Chowdhury; Perla Mariana Del Rio Estrada; Perla Maria Estrada Del Rio; Greg K Tharp; Ronald P Trible; Rama R Amara; Ann Chahroudi; Gustavo Reyes-Teran; Steven E Bosinger; Guido Silvestri
Journal:  J Immunol       Date:  2015-08-21       Impact factor: 5.422

4.  Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates.

Authors:  Lukas Flatz; Cheng Cheng; Lingshu Wang; Kathryn E Foulds; Sung-Youl Ko; Wing-Pui Kong; Rahul Roychoudhuri; Wei Shi; Saran Bao; John-Paul Todd; Mohammed Asmal; Ling Shen; Mitzi Donaldson; Stephen D Schmidt; Jason G D Gall; Daniel D Pinschewer; Norman L Letvin; Srinivas Rao; John R Mascola; Mario Roederer; Gary J Nabel
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

5.  Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody.

Authors:  John B Schell; Kapil Bahl; Nina F Rose; Linda Buonocore; Meredith Hunter; Preston A Marx; Celia C LaBranche; David C Montefiori; John K Rose
Journal:  Vaccine       Date:  2012-04-23       Impact factor: 3.641

6.  What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?

Authors:  Marina R Alexander; Rajesh Ringe; Rogier W Sanders; James E Voss; John P Moore; Per Johan Klasse
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

Review 7.  Enhancing poxvirus vectors vaccine immunogenicity.

Authors:  Juan García-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 8.  Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo.

Authors:  Natalie A Hutnick; Devin J F Myles; Chaoran Billie Bian; Karuppiah Muthumani; David B Weiner
Journal:  Curr Opin Virol       Date:  2011-09-07       Impact factor: 7.090

Review 9.  Harnessing CD4⁺ T cell responses in HIV vaccine development.

Authors:  Hendrik Streeck; M Patricia D'Souza; Dan R Littman; Shane Crotty
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

10.  Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.

Authors:  Charlotta Nilsson; Karina Godoy-Ramirez; Bo Hejdeman; Andreas Bråve; Lindvi Gudmundsdotter; David Hallengärd; Jeffrey R Currier; Lindsay Wieczorek; Klara Hasselrot; Patricia L Earl; Victoria R Polonis; Mary A Marovich; Merlin L Robb; Eric Sandström; Britta Wahren; Gunnel Biberfeld
Journal:  AIDS Res Hum Retroviruses       Date:  2013-11-15       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.